BSBhuvana A. Setty

Bhuvana A. Setty

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bhuvana A. Setty has a total of 247 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study

    by David S. Shulman, Kelly Klega, Nan Chen, Allen Buxton, Elliot Gohn, Sarah Sexton, Catherine Clinton, Mohammad Tanhaemami, Carrie Cibulskis, Edwin Choy, et al.

    PURPOSE: Identification of discrete risk groups remains a high priority for patients with Ewing sarcoma (EWS). We sought to prospectively validate circulating tumor DNA (ctDNA) as a prognostic factor and develop clinical-molecular risk groups. METHODS: We conducted a prospective investigator-initiated biology study for patients with localized EWS (LEOPARD) and embedded ctDNA analysis into the North American frontline metastatic study AEWS1221. Eligible patients were younger than 50 years with newly diagnosed EWS. All patients provided a baseline blood sample for analysis, which was subjected to ultralow-pass whole-genome sequencing and hybrid capture panel sequencing for ctDNA quantification, fusion detection, and characterization of STAG2 and TP53 alterations. Serial ctDNA sequencing was conducted on a subset of patients in each study. We tested for associations between ctDNA burden and secondary genomic events, and clinical features and outcomes. RESULTS: One hundred forty patients with localized disease and 255 with metastatic disease provided evaluable pretreatment samples for ctDNA analysis. Elevated baseline ctDNA was associated with stage, tumor size, primary site, indeterminate pulmonary nodules, and metastatic pattern. Elevated pretreatment ctDNA burden was associated with inferior outcomes in patients with localized (n = 140, hazard ratio [HR] = 2.36, P = .032) and metastatic disease (n = 255, HR = 2.15, P = .001). Patients with metastatic disease and TP53 variants and/or persistent on-therapy ctDNA had dismal outcomes. Patients with localized disease, low ctDNA, small tumors, and favorable genomics had no events and constitute a novel low-risk group. Among patients with metastatic disease, those with lung-only disease, low ctDNA, and favorable genomics represent an intermediate-risk group. CONCLUSION: This study prospectively validates pretreatment ctDNA burden as prognostic in EWS. Risk groups that integrate ctDNA burden with clinical-molecular features differentiate patients with low-, intermediate-, and high-risk disease.

  • Racial disparities in pediatric cancer hospitalizations in the United States

    by Tugce Kutuk, Raj Singh, Vedat Yildiz, Pranav Puri, Randal S. Olshefski, Marshall Harrell, Keri A. Streby, Terri L. Guinipero, Rolla D. Abu-Arja, Anthony N. Audino, et al.

  • Open Access

    New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee

    by Jessica D. Daley, Susan L. Whiteway, Christine M. Heske, Filemon S. Dela Cruz, Sarah B. Whittle, Sarah Cohen‐Gogo, Anderson B. Collier, Ajay Gupta, Joyce Ohm, Andrew Clark, et al.

    Outcomes for relapsed Ewing sarcoma remain consistently poor. Continued efforts to consider creative new approaches for the treatment of relapsed Ewing sarcoma are needed. The Children's Oncology Group Bone Tumor Committee convened a New Strategies for Ewing Sarcoma Task Force to systematically evaluate agents for inclusion in future Phase II or III clinical trials for relapsed Ewing sarcoma. In addition, the Task Force summarized the possible limitations of common trial designs and considered new approaches to study promising agents in clinical trials. Here, we summarize this work and propose next steps for future trials for relapsed Ewing sarcoma.


  • Open Access

    Local Control and Toxicity Outcomes After Stereotactic Body Radiation Therapy for Metastatic Osteosarcoma in Pediatric Patients

    by Sohil Reddy, Rituraj Upadhyay, Brett Klamer, Raj Singh, David Konieczkowski, Timothy Cripe, Nicholas D. Yeager, Ryan D. Roberts, Jennifer H. Aldrink, Bhuvana Setty, et al.

    Background: Pediatric osteosarcoma is an aggressive bone malignancy that presents significant challenges due to high rates of metastatic disease and relapse. It is often treated with palliative radiotherapy for symptom control, but achieving definitive local control (LC) with radiotherapy alone is challenging given its radioresistance. LC may be potentially improved by utilizing stereotactic body radiation therapy (SBRT) to deliver high biologically equivalent doses (BED).Methods: This study evaluated the LC outcomes of pediatric patients with osteosarcoma and unresectable metastatic disease who were treated with SBRT. Progression‐free survival (PFS), overall survival (OS), and toxicities were assessed as secondary endpoints.Results: The study included seven patients who received 34 courses of SBRT. The median age at diagnosis was 13.1 and 17.1 years at first SBRT. The common sites for SBRT were extraspinal osseous metastases (56%), pulmonary/mediastinal (29%), and spine (9%). At a median follow‐up of 6 months on a per‐lesion analysis, LC was achieved in 88% of lesions, with four lesions failing locally. All four local failures were found in patients receiving a BED ≤48 Gy. The median distant PFS was 2.4 months. Toxicities were present in four patients, all of which resolved with supportive treatment.Conclusions: Our study demonstrated that SBRT is safe and effective at achieving LC in pediatric patients with unresectable metastatic osteosarcoma, though distant progression can limit survival outcomes. Further studies evaluating SBRT in combination with other therapies are needed to address distant progression.


  • Comprehensive Genomic Characterization of Congenital and Infantile Cancers Reveals High Yield of Medically Meaningful Findings

    by Mariam T. Mathew, Samara L. Potter, Kathleen M. Schieffer, Julie O'DOnovan, Elizabeth A.R. Garfinkle, Sophia A. Paxton, Bhuvana Setty, Margot A. Lazow, Daniel R. Boue’, Elizabeth Varga, et al.

    PURPOSE: We describe findings from genomic profiling of tumors among infantile pediatric patients studied within a translational research protocol established at our pediatric tertiary care center. Comprehensive genomic profiling was initiated to aid in diagnosis, prognostication, treatment, and detection of germline disease predisposition in this patient cohort. METHODS: Enhanced exome sequencing of disease and comparator tissue was coupled with RNA sequencing of the disease-involved specimen to assess for single nucleotide variation, insertion/deletions, copy number alteration, structural variation, fusions, and methylation profiling–based tumor classification scores. RESULTS: Among 317 patients who consented to the protocol, 39 (12%) had infantile cancers diagnosed at ≤1 year of age. Germline genetic alteration was frequent with 11 of 39 patients (28%) harboring a pathogenic change. Clinically relevant findings affecting diagnosis, prognosis, therapy, or surveillance were identified in 37 of 39 (95%) patients. CONCLUSION: Our data support that a pediatric cohort gains significant benefit from a comprehensive profiling approach, with a high yield of clinically significant findings. Nearly half of the infants in this cancer cohort harbored tumors potentially susceptible to therapeutic targets on the basis of genomic profile, and among these, another half sought benefit from therapeutic implementation.


  • Salvage Therapy Efficacy is Modified by Risk Group at Diagnosis in Patients With Relapsed Rhabdomyosarcoma

    by Stephanie Fetzko, Abha A. Gupta, Bhuvana A. Setty, Mary Wedekind Malone, Jeremy Schraw, Philip J. Lupo, Heidi Russell, Lauren Nicholls, David Walterhouse, Douglas S. Hawkins, et al.

    Background: Patients with relapsed rhabdomyosarcoma (RMS) are treated with varying approaches and have a poor overall survival (OS). We performed an observational comparison of salvage regimens exploring whether high‐dose alkylator combinations were associated with longer OS.Procedure: We categorized 110 patients with relapsed RMS from five institutions into two groups, those treated with regimens including a high‐dose alkylator (Group A) and those treated without a high‐dose alkylator (Group B). We compared OS between the two, adjusting for risk group at diagnosis and institution using Kaplan–Meier and Cox proportional hazards analyses.Results: Median follow‐up in the 32 survivors was 4 years (range: 1.0–16.7 years) with a 28% (95% CI: 19%–37%) 4‐year OS. Group A patients had a longer OS compared to Group B (4‐year OS 41%, 95% CI: 27%–58%, vs. 14%, 95% CI: 4%–24%, respectively, p = 0.002). Adjustment for risk group at diagnosis abrogated the association (HR 1.4, 95% CI: 0.8–2.3, p = 0.16), while controlling for institution had no effect. In stratified analyses, patients with low risk at diagnosis had the highest effect size, suggesting a benefit after high‐dose alkylator regimens (stratified HR 4.4, 95% CI: 0.96–20.3, p = 0.06, reference Group A) compared to intermediate‐ (stratified HR 1.6, 95% CI: 0.9–3.2, p = 0.13) or high‐ (stratified HR 0.9, 95% CI: 0.4–1.8, p = 0.7) risk patients.Conclusions: Patients with relapsed RMS and low‐risk group at diagnosis may benefit from high‐dose alkylator chemotherapy, while the high‐risk group has a dismal outcome regardless of treatment selection. It is inconclusive whether intermediate‐risk patients may benefit from such therapy.


  • Open Access

    Data from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation

    by Aditi Dhir, Masanori Hayashi, Avery Bodlak, Javier Oesterheld, David M. Loeb, Leo Mascarenhas, Michael S. Isakoff, Eric S. Sandler, Scott C. Borinstein, Matteo Trucco, et al.

    Purpose:The combination of gemcitabine and docetaxel is often used to treat patients with recurrent osteosarcoma. Nab-paclitaxel has preclinical activity against osteosarcoma and is potentially less myelosuppressive than docetaxel. We conducted a prospective multi-institutional phase II trial combining gemcitabine and nab-paclitaxel for patients aged 12 to 30 years with recurrent osteosarcoma and measurable disease.Patients and Methods:A Simon’s two-stage design was used to test a 4-month progression-free survival (PFS-4) of 10% vs. 35%. Patients received nab-paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2 weekly × 3 in 4-week cycles. Immunohistochemical analysis of archival tissue and serial assessment of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) using ultralow passage whole-genome sequencing were performed to identify potential biomarkers of response.Results:Eighteen patients received 56 total cycles (median 2, range 1–12). Two patients (11%) experienced confirmed partial response and six (33%) received >2 cycles. The PFS-4 was 28% (95% confidence interval, 13%–59%). Six patients required dose reductions and three patients were removed due to toxicities. All 18 patients had detectable CTCs and 10 had ctDNA identified. All eight patients with MYC amplification at study entry experienced disease progression.Conclusions:Gemcitabine and nab-paclitaxel demonstrated similar clinical activity and toxicity compared to previous retrospective reports utilizing gemcitabine and docetaxel in patients with recurrent osteosarcoma. Serial analysis of CTC and ctDNA was feasible in this prospective multi-institution study and provides preliminary data on the use of these assays in patients with relapsed disease.

  • Open Access

    Supplementary Table S3 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation

    by Aditi Dhir, Masanori Hayashi, Avery Bodlak, Javier Oesterheld, David M. Loeb, Leo Mascarenhas, Michael S. Isakoff, Eric S. Sandler, Scott C. Borinstein, Matteo Trucco, et al.

    Supplemental Table S3. Detailed ctDNA results over the course of the study.

  • Open Access

    Supplementary Table S1 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation

    by Aditi Dhir, Masanori Hayashi, Avery Bodlak, Javier Oesterheld, David M. Loeb, Leo Mascarenhas, Michael S. Isakoff, Eric S. Sandler, Scott C. Borinstein, Matteo Trucco, et al.

    Supplementary Table S1. Representativeness of Study Participants

  • Open Access

    Supplementary Table S2 from Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation

    by Aditi Dhir, Masanori Hayashi, Avery Bodlak, Javier Oesterheld, David M. Loeb, Leo Mascarenhas, Michael S. Isakoff, Eric S. Sandler, Scott C. Borinstein, Matteo Trucco, et al.

    Supplemental Table S2. Immunohistochemistry Results and Clinical Benefit